Physician profile
Nowreen Haq
NPI 1114123395
$39,588.13
in general payments reported to CMS, 2019-2025
45 companies · $933 in 2025
The $933 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $205 · 2020: $113 · 2021: $1,119 · 2022: $20K · 2023: $14K · 2024: $2,454 · 2025: $933.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,412 · Honoraria: $5,000 · Food and Beverage: $4,569 · Travel and Lodging: $2,699 · Consulting Fee: $85.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,412.00 |
| Honoraria | $5,000.00 |
| Food and Beverage | $4,569.29 |
| Travel and Lodging | $2,699.10 |
| Consulting Fee | $85.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $18,160.58 | 2022-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $13,266.12 | 2021-2025 | |
| Horizon Therapeutics Plc | $1,446.80 | 2021-2023 | Tepezza |
| Medtronic, INC. | $1,134.62 | 2021-2025 | Minimed 780g, Minimed 770g |
| Lilly USA, LLC | $724.30 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Xeris Pharmaceuticals, INC. | $677.12 | 2022-2025 | Recorlev, Gvoke Hypopen |
| Novo Nordisk INC | $574.28 | 2020-2025 | Ozempic, Wegovy, Rybelsus |
| Sanofi-Aventis U.S. LLC | $487.03 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $411.66 | 2021-2024 | Breztri |
| Dexcom, INC. | $400.84 | 2021-2024 | Dexcom G6 Transmitter |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $261.14 | 2023-2025 | Lifevest |
| Kyowa Kirin, INC. | $191.20 | 2023-2025 | Crysvita |
| Genzyme Corporation | $185.00 | 2019 | |
| Biogen, INC. | $172.01 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $162.32 | 2021-2025 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $135.40 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $127.75 | 2023-2025 | Evenity, Prolia, Tepezza |
| Cequr Corporation | $109.34 | 2023-2025 | Cequr Simplicity |
| Esperion Therapeutics, INC. | $74.79 | 2024 | Nexletol |
| Alexion Pharmaceuticals, INC. | $74.64 | 2023-2025 | Strensiq |
| Tandem Diabetes Care, INC. | $62.40 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ascensia Diabetes Care US INC. | $61.11 | 2022 | |
| Abbvie INC. | $59.99 | 2021 | |
| Pfizer INC. | $53.98 | 2021-2025 | |
| Mannkind Corporation | $51.55 | 2023 | Afrezza |
| Radius Health, INC. | $51.30 | 2024 | Tymlos |
| Amneal Pharmaceuticals LLC | $51.24 | 2024-2025 | Unithroid |
| Recordati_rare_diseases_inc. | $33.05 | 2024 | Signifor Lar, Isturisa |
| Averitas Pharma INC. | $29.94 | 2024 | Qutenza |
| Merck Sharp & Dohme LLC | $29.60 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $28.61 | 2024 | Xarelto |
| Insulet Corporation | $27.86 | 2022-2023 | Omnipod |
| Soleno Therapeutics, INC. | $27.67 | 2025 | Vykat Xr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.13 | 2023 | Jardiance |
| Embecta Corp. | $26.94 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Actelion Pharmaceuticals US, INC. | $22.51 | 2024 | Opsumit, Uptravi |
| Medtronic Minimed, INC. | $21.64 | 2020 | |
| Endo Pharmaceuticals INC. | $20.17 | 2019 | |
| Amryt Pharma Holdings Ltd | $19.71 | 2023 | Mycapssa |
| Rhythm Pharmaceuticals, INC. | $19.31 | 2024 | Imcivree |
| Otsuka America Pharmaceutical, INC. | $18.97 | 2021 | |
| Ibsa Pharma INC. | $18.38 | 2023 | Tirosint, Licart |
| Irhythm Technologies, INC. | $18.14 | 2021 | |
| Nestle Healthcare Nutrition INC. | $16.42 | 2021 | |
| Chiesi USA, INC. | $13.57 | 2024 | Myalept |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$61,567.78 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nowreen Haq listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.